Open Access

Establishing an EU-China consortium on traditional Chinese medicine research

  • Halil Uzuner1Email author,
  • Tai-Ping Fan2,
  • Alberto Dias3,
  • De-an Guo4,
  • Hani S El-Nezami5 and
  • Qihe Xu1
Chinese Medicine20105:42

DOI: 10.1186/1749-8546-5-42

Received: 20 October 2010

Accepted: 14 December 2010

Published: 14 December 2010

Abstract

Traditional Chinese medicine (TCM) is widely used in the European Union (EU) and attracts intense research interests from European scientists. As an emerging area in Europe, TCM research requires collaboration and coordination of actions. Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era, also known as GP-TCM, is the first ever EU-funded 7th Framework Programme (FP7) coordination action, aiming to inform the best practice and harmonise research on the safety and efficacy of TCM through interdisciplinary exchange of experience and expertise among clinicians and scientists. With its increasingly large pool of expertise across 19 countries including 13 EU member states, Australia, Canada, China, Norway, Thailand and the USA, the consortium provides forums and collaboration platforms on quality control, extraction technology, component analysis, toxicology, pharmacology and regulatory issues of Chinese herbal medicine (CHM), as well as on acupuncture studies, with a particular emphasis on the application of a functional genomics approach. The project officially started in May 2009 and by the time of its conclusion in April 2012 a Europe-based academic society dedicated to TCM research will be founded to carry on the mission of GP-TCM.

Introduction

Traditional Chinese medicine (TCM), especially Chinese herbal medicine (CHM) and acupuncture, is an ancient medical system used in China and other Asian countries for thousands of years [1, 2]. In contrast to the reductionist approach of Western medicine based on modern anatomy, physiology, pathology, pharmacology as well as cell and molecular biology, TCM uses a unique system and an individualised and holistic approach to describe health and disease, based on the philosophy of Yin-Yang balance and an emphasis on harmony of functions. These two medical systems differ greatly in many respects. In the past seven years, a number of international organisations were established in mainland China, Hong Kong and Macao, including the World Federation of Chinese Medicine Societies (WFCMS, September 2003), the Consortium for Globalisation of Chinese Medicine (CGCM, December 2003) and the International Society for Chinese Medicine (ISCM, 2004).

The Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era (GP-TCM) consortium was launched by the European Commission on the 1st May 2009. This is a three-year coordination action project funded under the EU Seventh Framework Programme (FP7) with a total budget of €995,100. The central hypothesis of the consortium is that, using functional genomics technology, which allows high-content observations of whole profiles of molecules at different levels, eg DNA, mRNA, protein and metabolites, and furthermore linking them to clinically relevant biological functions, we might be in a better position than ever before to interpret and validate the scientific value of TCM in a holistic and function-oriented manner [311].

Objectives

Focusing on research of CHM and acupuncture, we especially emphasise studies of CHMs, their complex chemical ingredients and their holistic impact on the functional genomics of patients. The overall aim of the consortium is to inform the best practice and harmonise research on the safety and efficacy of TCM using a functional genomics approach through exchange of opinions, experience and expertise among scientists in EU member states, China and other parts of the world. Specifically, we aim to undertake the following objectives:

  • Develop a European-Chinese network, collaborating on functional genomics research of TCM;

  • Review current practice of TCM research, identify problems and propose solutions;

  • Propose standard protocols of methodology;

  • Propose priority areas for future research;

  • Develop online resources to support and enhance pan-European studies of TCM research;

  • Facilitate and foster a sustainable European collaboration by founding a European society dedicated to TCM research.

Structure

As shown in Figure 1 through ten working groups known as work packages (WPs), the consortium takes actions to review the techniques, identify problems and solutions in the quality control (WP1), extraction and analysis (WP2) of CHMs. While these fundamental issues are addressed, discussion forums emphasising the use of functional genomics methodology in research of the safety, efficacy and mechanisms of CHMs (WP3-WP7) and acupuncture (WP8) form the core of this coordination project. The project covers toxicology (WP3), in vitro and in vivo pharmacology (WP4-WP5), clinical studies (WP6), as well as international regulatory issues of CHM (WP7). WP9 is dedicated to organising the Final Conference of the consortium at the end of the project and WP10 is charged to manage consortium-wide matters, such as appointment and coordination of WP leadership, recruitment of additional experts, editing website and newsletters, drafting standard operating procedures, providing scientific and technological support and guidance, organising internal review and quality assurance, as well as liaising with the Commission and other stakeholders and external authorities.
https://static-content.springer.com/image/art%3A10.1186%2F1749-8546-5-42/MediaObjects/13020_2010_Article_101_Fig1_HTML.jpg
Figure 1

Structure of the GP-TCM Consortium. GP-TCM work package interaction and relationship: GP-TCM has ten interactive working groups, known as work packages (WP). WP1-WP7 specialises in quality control, component extraction and chemical analysis, toxicology, in vitro and in vivo pharmacology, clinical studies and regulatory issues in commercial R&D respectively. WP8 is specialised in acupuncture studies and WP9 is dedicated to organising the Final conference of the consortium, at which a new European society will be launched to succeed the mission of the consortium. WP10 is the managing, coordinating and leading body of the whole consortium, aiming at integrating the expertise and collating outputs of all WPs to achieve the overall objectives of the consortium.

Membership

As shown in Table 1 the consortium has 27 beneficiary (ie funded) partner organisations across ten EU member states (ie Austria, Belgium, Estonia, Germany, Ireland, Italy, the Netherlands, Portugal, Spain and the UK) and China, which is an International Cooperation Partner Country (ICPC) of the EU. The consortium has additional 60 non-beneficiary (ie unfunded) collaborating partner organisations as well as two independent experts from Australia, Austria, Belgium, China, Denmark, Finland, Germany, Italy, Luxembourg, the Netherlands, Norway, Thailand, the UK and the USA (Table 2). Please refer to the project website at http://​www.​gp-tcm.​org/​about/​partners/​ for an updated list of consortium partners. This forms a diverse, multicultural and multidisciplinary team of about 150 principal investigators, including leading scientists, clinicians, TCM practitioners, as well as experts in industrial development and regulatory issues. Non-beneficiary membership is mainly based on consortium invitation and requires outstanding expertise needed for the project. Interested parties are welcome to contact us via the GP-TCM website http://​www.​gp-tcm.​org/​contact/​. GP-TCM currently covers half of the 27 EU member states and its members in China are largely in major eastern and southern cities. As an open-ended consortium, GP-TCM welcomes interested parties from all EU member states and China to join our network, sharing resources and forging collaborations. We will continue to develop and strengthen collaborations with friends in Africa, South America, Asia and non-EU European countries to exchange experience and lessons learnt in the research of traditional medicines.
Table 1

GP-TCM beneficiary members

GP-TCM beneficiary partners

Country

Contact

King's College London

UK

Dr. Qihe Xu

University of Vienna

Austria

Prof. Verena M. Dirsch

L'Université Libre de Bruxelles

Belgium

Prof. Pierre Duez

Beijing University of Chinese Medicine

China

Prof Yanjiang Qiao

China Capital Medical University

China

Prof. Xiaomin Wang

Institute of Medicinal Plant Development

China

Prof. Xinmin Liu

Shanghai Institute of Acupuncture-Moxibustion

China

Prof. Huangan Wu

Shanghai University of Traditional Chinese Medicine

China

Dr. Liu Chenghai

University of Hong Kong

China

Dr. Hani El-Nezami

Asper Biotech Ltd

Estonia

Ms. Janne Üksti

Federal Institute for Drugs and Medical Devices

Germany

Dr. Werner Knöss

University of Düsseldorf

Germany

Prof. Peter Proksch

University of Munich

Germany

Prof. Angelika Vollmar

University of Bonn

Germany

Prof. Gabriele König

Trinity College Dublin

Ireland

Dr. Helen Sheridan

University of Milan

Italy

Prof. Enrica Bosisio

University of Padova

Italy

Prof. Maria Carrara

CMC Tasly Group BV

The Netherlands

Dr. You-Ping Zhu

Leiden University

The Netherlands

Prof. Robert Verpoorte

University of Minho

Portugal

Prof. Alberto Dias

University of Alcala

Spain

Prof. F. Javier de Lucio Cazaña

University Hospital Ramón y Cajal-FIBIO

Spain

Dr. M. Laura García Bermejo

Acu-herb Consultant, Sheffield

UK

Ms. Dan Jiang

University of Wolverhampton

UK

Prof. Kelvin Chan

Royal Botanic Gardens, Kew

UK

Prof. Monique Simmonds

University of Southampton

UK

Prof. George Lewith

University of Cambridge

UK

Dr. Tai-Ping Fan

Table 2

GP-TCM non-beneficiary members

GP-TCM Non-beneficiary partners

Country

Contact

University of Western Sydney

Australia

Prof. Alan Bensoussan

University of Graz

Austria

Prof. Rudolf Bauer

University of Mons

Belgium

Prof. Jean-Marie Colet

Beijing East Linden Science and Technology Co. Ltd.

China

Prof. Yanhuai Liu

China Academy of Chinese Medical Sciences

China

Prof. Aiping Lu

China-Japan Friendship Hospital

China

Prof. Ping Li

Dalian Institute of Chemical Physics

China

Prof. Xinmiao Liang

Hong Kong Baptist University

China

Prof. Zhongzhen Zhao

Hong Kong Buddhist Hospital

China

Prof. Vivian Wong

Jinan University

China

Prof. Xinsheng Yao

Peking University

China

Prof. Wenhan Lin

PuraPharm

China

Mr. Abraham Chan

Shanghai Innovation Research Centre of Traditional Medicine

China

Prof. William Weiguo Jia

Shanghai Jiaotong University

China

Prof. Liping Zhao

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

China

Prof. De-an Guo

Tongji University

China

Prof. Gang Pei

Tasly Institute of Tasly Group Co., Ltd.

China

Ms. Karolina J. Svedlund

Tianjin University of Traditional Chinese Medicine

China

Prof. Boli Zhang

University of Macau

China

Prof. Yi-Tao Wang

The Chinese University of Hong Kong

China

Prof. Ge Lin

Pfizer Corporation Hong Kong Ltd

China

Mr. Stephen Leung

State Food and Drug Administration

China

Prof. Zhong-zhi Qian

National Research Institute of Chinese Medicine, Taiwan

China

Prof. Yi-Tsau Huang

University of Aarhus

Denmark

Prof. Brian Clark

University of Oulu

Finland

Prof. Olavi Pelkonen

Public Research Centre of Health

Luxembourg

Dr. Ning Wang

Charité University Medical Center

Germany

Prof. Claudia M. Witt

Johannes Gutenberg University

Germany

Dr. Huige Li

University of Regensburg

Germany

Prof. Gerhard Franz

Philipps - Universität Marburg

Germany

Prof. Shuming Li

Max Planck Institute for Biophysics

Germany

Prof. Wolfgang Schwarz

Dr Willmar Schwabe GmbH & Co. KG

Germany

Dr. Günter Meng

Caesar & Loretz GmbH

Germany

Dr. Mirko Bayer

University of Cagliari

Italy

Prof. Enzo Tramontano

University of Rome Tor Vergata

Italy

Prof. Giovanna M. Franconi

Institute of Neurobiology and Molecular Medicine, Italian National Research Council

Italy

Dr. Luigi Manni

SU BioMedicine

The Netherlands

Prof. Jan van der Greef

Norwegian University of Science and Technology

Norway

Prof. Odd Georg Nilsen

Thailand Ministry of Public Health

Thailand

Dr. Prat Boonyawongviroj

School of Pharmacy

UK

Prof. Michael Heinrich

Brunel University

UK

Prof. Ian A. Sutherland

University of Reading

UK

Prof. Elizabeth Williamson

Guy's & St Thomas' NHS Foundation Trust

UK

Prof. Debbie Shaw

University of Nottingham

UK

Prof. Sue Watson

University of Warwick

UK

Prof. Kenneth Muir

University of Westminster

UK

Dr. Volker Scheid

University of Lincoln

UK

Dr. Huijun Shen

Thames Valley University

UK

Prof. Nicola Robinson

University of the West England

UK

Prof. Quan Min Zhu

Imperial College London

UK

Dr. Daqing Ma

Global Regulatory Services

UK

Mrs. Greer Deal

Link China Pharma Solutions

UK

Mr. Marshall Ma

University of Oxford

UK

Ms. Rebecca Richmond

University of East London

UK

Dr. Tianjun Wang

Pharsafer Associates Limited

UK

Dr. Graeme Ladds

Avicenna

UK

Mr. Mazin Al-Khafaji

University of Louisville

USA

Prof. Y. James Kang

Yale University

USA

Prof. Yung-Chi Cheng

U.S. Food and Drug Administration

USA

Dr. Shaw T. Chen

Vanderbilt University Medical Center

USA

Dr. Lijun Ma

Independent

UK

Dr. Shouming Zhong

Independent

UK

Dr. Daryl Rees

Progress and difficulties

During the first 18 months of the project (May 2009-October 2010), the management team (WP10) has coordinated a highly successful team build-up and re-construction. With the ever-strengthening expertise pool, WP10 has developed a number of committees and panels that lead the consortium with clear divisions of labour. WP10 has led the design and updates of the professional GP-TCM website and all WPs have established their homepages and online discussion facilities. Periodic newsletters have enabled members to share information and stay as a united team. Significantly, a series of face-to-face meetings, including consortium and WP kick-off meetings and the 1st Annual General Meeting, have been organised to monitor the consortium, promote interactions and collaborations and ensure milestones are met and deliverables accomplished on time and in high quality.

Noteworthy WP-specific achievements are as follows. WP1 led the creation of a list of nearly 300 species of plants and fungi commonly used in TCM in Europe and China and a priority list of 11 species will be used by all WPs in their initial literature analysis. WP2 worked jointly with WP1, linking quality control, extraction technology and chemical analysis, with special emphasis on the important role of paozhi (processing) in the production of CHM. WP3 produced a list of toxic plants for further literature study and identified 3 major fields of action: (i) investigation of methods (classical and functional genomics) applicable to toxicity evaluation; (ii) study of toxicological reports available on a series of CHM; (iii) review of pharmacovigilance safety data. WP4 established evaluation criteria for scoring scientific articles and began the creation of an appropriate database of literature encompassing functional genomic applications in CHM research. WP5 performed reviews on CHM literature involving animal models, especially models of cancer and its conclusions have laid a solid foundation for further literature analysis on application of functional genomics in CHM research and proposing good practice in animal studies of CHM. WP6 gathered literature on seminal studies in clinical CHM studies and drafted a guideline on clinical trials of CHM. WP6 and WP8 collaboratively designed an online survey targeting TCM practitioners and the survey is currently undergoing in collaboration with 30 professional acupuncture and TCM organisations. WP7 brought together wide-ranging experiences and expertise in drug development and registration from Europe, China, Australia and North America to discuss the legislative and regulatory issues relevant to CHM. Together they are developing a comprehensive document providing comparisons of different practices on CHM regulations and this will be extremely helpful for the EU to develop its future policies and for companies to develop products for the global market. WP9 discussed the time and format of the Final Conference and preliminary bookings of venue has been made.

The major difficulty encountered by the consortium is unsurprisingly the language barrier. There is a lack of accessibility to original Chinese publications in Europe, and even if they are available, fast and accurate translation of these materials is impossible, preventing the consortium from extensively studying classic Chinese medical literature and evaluating a great deal of modern Chinese medical literature. While we strongly encourage our members to master both English and Chinese languages, we welcome members from various linguistic, ethnic and cultural backgrounds to work in close collaboration.

Further work

As the first ever EU-China collaborative consortium dedicated to TCM research, we will continue to promote EU-China dialogues and collaborations in this important emerging supra-disciplinary area. As a network of principal investigators, we will collaborate to train the next generation of scientists who are more comprehensively equipped to study complex drugs such as CHM and personalised medicine such as TCM. As a coordination action involving much literature review and evaluation, we acknowledge the huge importance of good practice in scientific publication and will continue to support open-access publications.

Concluding remarks

As an EU-China collaboration dedicated to TCM research, we are keen to incorporate ourselves into the worldwide landscape of TCM research community and serve as a constructive member. We sincerely support the international TCM community to bundle forces to improve TCM research funding from both the public and private sectors and to help shape the medicine of tomorrow together.

Abbreviations

CGCM: 

Consortium for Globalisation of Chinese Medicine

CHM: 

Chinese herbal medicines

EU: 

European Union

FP7: 

Seventh Framework Programme

GP-TCM: 

Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era

ICPC: 

International Cooperation Partner Country

ISCM: 

International Society for Chinese Medicine

TCM: 

Traditional Chinese medicine

WFCMS: 

World Federation of Chinese Medicine Societies

WPs: 

work packages.

Declarations

Acknowledgements

This work has received funding from the European Union's Framework Programme 7 [FP7/2007-2013] under the grant agreement No 223154. The consortium thanks the European Commission for the grant, and the Chinese government, Innovation China UK and many other advisory bodies for their generous support.

Authors’ Affiliations

(1)
Department of Renal Medicine, King's College London
(2)
Department of Pharmacology, University of Cambridge
(3)
CITAB-UM, Department of Biology, University of Minho
(4)
Shanghai Research Centre for TCM Modernization, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
(5)
School of Biological Sciences, University of Hong Kong

References

  1. Nestler G: Traditional Chinese medicine. Med Clin North Am. 2002, 86 (1): 63-73. 10.1016/S0025-7125(03)00072-5.View ArticlePubMed
  2. Normile D: Asian medicine. The new face of traditional Chinese medicine. Science. 2003, 299 (5604): 188-90. 10.1126/science.299.5604.188.View ArticlePubMed
  3. Tilton R, Paiva AA, Guan JQ, Marathe R, Jiang Z, van Eyndhoven W, Bjoraker J, Prusoff Z, Wang H, Liu SH, Cheng YC: A comprehensive platform for quality control of botanical drugs (PhytomicsQC): A case study of Huangqin Tang (HQT) and PHY906. Chin Med. 2010, 5 (1): 30-10.1186/1749-8546-5-30.PubMed CentralView ArticlePubMed
  4. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu SH, Cheng YC: The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2010, 2 (45): 45ra59-View ArticlePubMed
  5. Van Wietmarschen H, Yuan K, Lu C, Gao P, Wang J, Xiao C, Yan X, Wang M, Schroën J, Lu A, Xu G, van der Greef J: Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients. J Clin Rheumatol. 2009, 15 (7): 330-7. 10.1097/RHU.0b013e3181ba3926.View ArticlePubMed
  6. Lao YM, Jiang JG, Yan L: Application of metabonomic analytical techniques in the modernization and toxicology research of traditional Chinese medicine. Br J Pharmacol. 2009, 157 (7): 1128-41. 10.1111/j.1476-5381.2009.00257.x.PubMed CentralView ArticlePubMed
  7. Kang YJ: Herbogenomics: from traditional Chinese medicine to novel therapeutics. Exp Biol Med (Maywood). 2008, 233 (9): 1059-65. 10.3181/0802-MR-47.View Article
  8. Li SS: Commentary-the proteomics: A new tool for Chinese medicine research. Am J Chin Med. 2007, 35 (6): 923-8. 10.1142/S0192415X07005387.View ArticlePubMed
  9. Cho WC: Application of proteomics in Chinese medicine research. Am J Chin Med. 2007, 35 (6): 911-22. 10.1142/S0192415X07005375.View ArticlePubMed
  10. Gao M, Deng C, Lin S, Hu F, Tang J, Yao N, Zhang X: Recent developments and contributions from Chinese scientists in multidimensional separations for proteomics and traditional Chinese medicines. J Sep Sci. 2007, 30 (6): 785-91. 10.1002/jssc.200600372.View ArticlePubMed
  11. Efferth T, Koch E: Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets. 2010,

Copyright

© Uzuner et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement